Detailed TOC of Global PD-1 and PDL-1 Inhibitors Market Research Report 2025
1 PD-1 and PDL-1 Inhibitors Market Overview
1.1 Product Definition
1.2 PD-1 and PDL-1 Inhibitors by Type
1.2.1 Global PD-1 and PDL-1 Inhibitors Market Value Comparison by Type (2024 VS 2031)
1.2.2 Pembrolizumab
1.2.3 Nivolumab
1.2.4 Atezolizumab
1.2.5 Durvalumab
1.2.6 Avelumab
1.3 PD-1 and PDL-1 Inhibitors by Application
1.3.1 Global PD-1 and PDL-1 Inhibitors Market Value by Application (2024 VS 2031)
1.3.2 Stomach Cancer
1.3.3 Liver Cancer
1.3.4 Kidney Ccancer
1.3.5 Bladder Cancer
1.3.6 Cervical Cancer
1.3.7 Other
1.4 Global PD-1 and PDL-1 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global PD-1 and PDL-1 Inhibitors Revenue 2020-2031
1.4.2 Global PD-1 and PDL-1 Inhibitors Sales 2020-2031
1.4.3 Global PD-1 and PDL-1 Inhibitors Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 PD-1 and PDL-1 Inhibitors Market Competition by Manufacturers
2.1 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Manufacturers (2020-2025)
2.2 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Manufacturers (2020-2025)
2.3 Global PD-1 and PDL-1 Inhibitors Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of PD-1 and PDL-1 Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of PD-1 and PDL-1 Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PD-1 and PDL-1 Inhibitors, Product Type & Application
2.7 Global Key Manufacturers of PD-1 and PDL-1 Inhibitors, Date of Enter into This Industry
2.8 Global PD-1 and PDL-1 Inhibitors Market Competitive Situation and Trends
2.8.1 Global PD-1 and PDL-1 Inhibitors Market Concentration Rate
2.8.2 The Global 5 and 10 Largest PD-1 and PDL-1 Inhibitors Players Market Share by Revenue
2.8.3 Global PD-1 and PDL-1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global PD-1 and PDL-1 Inhibitors Market Scenario by Region
3.1 Global PD-1 and PDL-1 Inhibitors Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global PD-1 and PDL-1 Inhibitors Sales by Region: 2020-2031
3.2.1 Global PD-1 and PDL-1 Inhibitors Sales by Region: 2020-2025
3.2.2 Global PD-1 and PDL-1 Inhibitors Sales by Region: 2026-2031
3.3 Global PD-1 and PDL-1 Inhibitors Revenue by Region: 2020-2031
3.3.1 Global PD-1 and PDL-1 Inhibitors Revenue by Region: 2020-2025
3.3.2 Global PD-1 and PDL-1 Inhibitors Revenue by Region: 2026-2031
3.4 North America PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.4.1 North America PD-1 and PDL-1 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America PD-1 and PDL-1 Inhibitors Sales by Country (2020-2031)
3.4.3 North America PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.5.1 Europe PD-1 and PDL-1 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe PD-1 and PDL-1 Inhibitors Sales by Country (2020-2031)
3.5.3 Europe PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PD-1 and PDL-1 Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific PD-1 and PDL-1 Inhibitors Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific PD-1 and PDL-1 Inhibitors Sales by Region (2020-2031)
3.6.3 Asia Pacific PD-1 and PDL-1 Inhibitors Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.7.1 Latin America PD-1 and PDL-1 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America PD-1 and PDL-1 Inhibitors Sales by Country (2020-2031)
3.7.3 Latin America PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PD-1 and PDL-1 Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa PD-1 and PDL-1 Inhibitors Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa PD-1 and PDL-1 Inhibitors Sales by Country (2020-2031)
3.8.3 Middle East and Africa PD-1 and PDL-1 Inhibitors Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PD-1 and PDL-1 Inhibitors Sales by Type (2020-2031)
4.1.1 Global PD-1 and PDL-1 Inhibitors Sales by Type (2020-2025)
4.1.2 Global PD-1 and PDL-1 Inhibitors Sales by Type (2026-2031)
4.1.3 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Type (2020-2031)
4.2 Global PD-1 and PDL-1 Inhibitors Revenue by Type (2020-2031)
4.2.1 Global PD-1 and PDL-1 Inhibitors Revenue by Type (2020-2025)
4.2.2 Global PD-1 and PDL-1 Inhibitors Revenue by Type (2026-2031)
4.2.3 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Type (2020-2031)
4.3 Global PD-1 and PDL-1 Inhibitors Price by Type (2020-2031)
5 Segment by Application
5.1 Global PD-1 and PDL-1 Inhibitors Sales by Application (2020-2031)
5.1.1 Global PD-1 and PDL-1 Inhibitors Sales by Application (2020-2025)
5.1.2 Global PD-1 and PDL-1 Inhibitors Sales by Application (2026-2031)
5.1.3 Global PD-1 and PDL-1 Inhibitors Sales Market Share by Application (2020-2031)
5.2 Global PD-1 and PDL-1 Inhibitors Revenue by Application (2020-2031)
5.2.1 Global PD-1 and PDL-1 Inhibitors Revenue by Application (2020-2025)
5.2.2 Global PD-1 and PDL-1 Inhibitors Revenue by Application (2026-2031)
5.2.3 Global PD-1 and PDL-1 Inhibitors Revenue Market Share by Application (2020-2031)
5.3 Global PD-1 and PDL-1 Inhibitors Price by Application (2020-2031)
6 Key Companies Profiled
6.1 GlaxoSmithKline plc
6.1.1 GlaxoSmithKline plc Company Information
6.1.2 GlaxoSmithKline plc Description and Business Overview
6.1.3 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GlaxoSmithKline plc PD-1 and PDL-1 Inhibitors Product Portfolio
6.1.5 GlaxoSmithKline plc Recent Developments/Updates
6.2 Bristol-Myers Squibb Company
6.2.1 Bristol-Myers Squibb Company Company Information
6.2.2 Bristol-Myers Squibb Company Description and Business Overview
6.2.3 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bristol-Myers Squibb Company PD-1 and PDL-1 Inhibitors Product Portfolio
6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.3 Arcus Biosciences, Inc.
6.3.1 Arcus Biosciences, Inc. Company Information
6.3.2 Arcus Biosciences, Inc. Description and Business Overview
6.3.3 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Arcus Biosciences, Inc. PD-1 and PDL-1 Inhibitors Product Portfolio
6.3.5 Arcus Biosciences, Inc. Recent Developments/Updates
6.4 Agenus Inc
6.4.1 Agenus Inc Company Information
6.4.2 Agenus Inc Description and Business Overview
6.4.3 Agenus Inc PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Agenus Inc PD-1 and PDL-1 Inhibitors Product Portfolio
6.4.5 Agenus Inc Recent Developments/Updates
6.5 F. Hoffmann-La Roche Ltd
6.5.1 F. Hoffmann-La Roche Ltd Company Information
6.5.2 F. Hoffmann-La Roche Ltd Description and Business Overview
6.5.3 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.5.4 F. Hoffmann-La Roche Ltd PD-1 and PDL-1 Inhibitors Product Portfolio
6.5.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates
6.6 Astra Zeneca PLC
6.6.1 Astra Zeneca PLC Company Information
6.6.2 Astra Zeneca PLC Description and Business Overview
6.6.3 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Astra Zeneca PLC PD-1 and PDL-1 Inhibitors Product Portfolio
6.6.5 Astra Zeneca PLC Recent Developments/Updates
6.7 Beigene Ltd
6.7.1 Beigene Ltd Company Information
6.7.2 Beigene Ltd Description and Business Overview
6.7.3 Beigene Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Beigene Ltd PD-1 and PDL-1 Inhibitors Product Portfolio
6.7.5 Beigene Ltd Recent Developments/Updates
6.8 Incyte Corporation
6.8.1 Incyte Corporation Company Information
6.8.2 Incyte Corporation Description and Business Overview
6.8.3 Incyte Corporation PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Incyte Corporation PD-1 and PDL-1 Inhibitors Product Portfolio
6.8.5 Incyte Corporation Recent Developments/Updates
6.9 Biocad
6.9.1 Biocad Company Information
6.9.2 Biocad Description and Business Overview
6.9.3 Biocad PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Biocad PD-1 and PDL-1 Inhibitors Product Portfolio
6.9.5 Biocad Recent Developments/Updates
6.10 CStone Pharmaceuticals
6.10.1 CStone Pharmaceuticals Company Information
6.10.2 CStone Pharmaceuticals Description and Business Overview
6.10.3 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.10.4 CStone Pharmaceuticals PD-1 and PDL-1 Inhibitors Product Portfolio
6.10.5 CStone Pharmaceuticals Recent Developments/Updates
6.11 Ono Pharmaceutical
6.11.1 Ono Pharmaceutical Company Information
6.11.2 Ono Pharmaceutical Description and Business Overview
6.11.3 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Ono Pharmaceutical PD-1 and PDL-1 Inhibitors Product Portfolio
6.11.5 Ono Pharmaceutical Recent Developments/Updates
6.12 Merck
6.12.1 Merck Company Information
6.12.2 Merck Description and Business Overview
6.12.3 Merck PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Merck PD-1 and PDL-1 Inhibitors Product Portfolio
6.12.5 Merck Recent Developments/Updates
6.13 Shanghai Junshi Bioscience Co. Ltd
6.13.1 Shanghai Junshi Bioscience Co. Ltd Company Information
6.13.2 Shanghai Junshi Bioscience Co. Ltd Description and Business Overview
6.13.3 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Shanghai Junshi Bioscience Co. Ltd PD-1 and PDL-1 Inhibitors Product Portfolio
6.13.5 Shanghai Junshi Bioscience Co. Ltd Recent Developments/Updates
6.14 Shanghai Henlius Biotech, Inc.
6.14.1 Shanghai Henlius Biotech, Inc. Company Information
6.14.2 Shanghai Henlius Biotech, Inc. Description and Business Overview
6.14.3 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Shanghai Henlius Biotech, Inc. PD-1 and PDL-1 Inhibitors Product Portfolio
6.14.5 Shanghai Henlius Biotech, Inc. Recent Developments/Updates
6.15 Jiangsu HengRui Medicine Co., Ltd.
6.15.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
6.15.2 Jiangsu HengRui Medicine Co., Ltd. Description and Business Overview
6.15.3 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Jiangsu HengRui Medicine Co., Ltd. PD-1 and PDL-1 Inhibitors Product Portfolio
6.15.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PD-1 and PDL-1 Inhibitors Industry Chain Analysis
7.2 PD-1 and PDL-1 Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PD-1 and PDL-1 Inhibitors Production Mode & Process Analysis
7.4 PD-1 and PDL-1 Inhibitors Sales and Marketing
7.4.1 PD-1 and PDL-1 Inhibitors Sales Channels
7.4.2 PD-1 and PDL-1 Inhibitors Distributors
7.5 PD-1 and PDL-1 Inhibitors Customer Analysis
8 PD-1 and PDL-1 Inhibitors Market Dynamics
8.1 PD-1 and PDL-1 Inhibitors Industry Trends
8.2 PD-1 and PDL-1 Inhibitors Market Drivers
8.3 PD-1 and PDL-1 Inhibitors Market Challenges
8.4 PD-1 and PDL-1 Inhibitors Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Download FREE Sample Report
